Amjad Ibraim Oraibi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amjad Ibraim Oraibi has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Hany Akeel Al-Hussaniy
Department of Pharmacology, College of Pharmacy, Al-nisour University, Baghdad, Iraq
3 shared publications - Ahmed Saeed Hamad
Albayan University, Baghdad, Iraq
1 shared publication - Angham M. Abed
Al Safwa University College, Karbala, Iraq
1 shared publication - Attaa S. Dawood
Al-Zahraa University for Women, Karbala, Iraq
1 shared publication - Bassam A. Al-Zubaidi
Bilad Alrafidain University, Diyala, Iraq
1 shared publication - Fatmah M. Alqahtani
Department of Biology College of Science King Khalid University Abha Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 29 October 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (41) , e74995
Structure‐Guided Identification of Flavonoid Inhibitors Targeting PE_PGRS17 in Mycobacterium tuberculosis : Insights From an Integrated In Silico Strategy
PE_PGRS17, a surface‐associated antigen of Mycobacterium tuberculosis (Mtb), contributes to immune evasion and intracellular survival within macrophages and therefore represents a potentially relevant but underexplored therapeutic target. Here, a curated library of flavonoid compounds was screened against PE_PGRS17 using structure‐based computational methods. Among the candidates, compounds PubChem CID 452707 and 5280352 emerged as the most promising, with binding affinities of −11.5 and −8.471 kcal/mol, respectively. Detailed interaction profiling revealed multiple hydrogen bonds and extensive hydrophobic contacts with key residues, including Val223, Thr306, Thr320, His221 , and Val308 , anchoring the ligands within the predicted binding pocket. Molecular dynamics simulations over 200 ns confirmed that both ligands remained stably associated with PE_PGRS17, with protein RMSD values equilibrating within 1.5–2.0 Å and ligand fluctuations confined to rotatable bonds. Secondary structure analysis demonstrated that α‐helices and β‐strands were preserved throughout the trajectories, while MM‐GBSA binding free energy calculations supported sustained binding, with compound PubChem CID 452707 at −47.7 kcal/mol and compound PubChem CID 5280352 at ‐68.6 kcal/mol at 200 ns. Thus, these findings suggest that PE_PGRS17 warrants further investigation as a druggable target and that flavonoids may provide useful starting scaffolds for anti‐tubercular lead discovery.
- 29 October 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (41) , e74995
Open AccessStructure‐Guided Identification of Flavonoid Inhibitors Targeting PE_PGRS17 in Mycobacterium tuberculosis : Insights From an Integrated In Silico Strategy
PE_PGRS17, a surface‐associated antigen of Mycobacterium tuberculosis (Mtb), contributes to immune evasion and intracellular survival within macrophages and therefore represents a potentially relevant but underexplored therapeutic target. Here, a curated library of flavonoid compounds was screened against PE_PGRS17 using structure‐based computational methods. Among the candidates, compounds PubChem CID 452707 and 5280352 emerged as the most promising, with binding affinities of −11.5 and −8.471 kcal/mol, respectively. Detailed interaction profiling revealed multiple hydrogen bonds and extensive hydrophobic contacts with key residues, including Val223, Thr306, Thr320, His221 , and Val308 , anchoring the ligands within the predicted binding pocket. Molecular dynamics simulations over 200 ns confirmed that both ligands remained stably associated with PE_PGRS17, with protein RMSD values equilibrating within 1.5–2.0 Å and ligand fluctuations confined to rotatable bonds. Secondary structure analysis demonstrated that α‐helices and β‐strands were preserved throughout the trajectories, while MM‐GBSA binding free energy calculations supported sustained binding, with compound PubChem CID 452707 at −47.7 kcal/mol and compound PubChem CID 5280352 at ‐68.6 kcal/mol at 200 ns. Thus, these findings suggest that PE_PGRS17 warrants further investigation as a druggable target and that flavonoids may provide useful starting scaffolds for anti‐tubercular lead discovery.
- Open Access
- 12 February 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, 1-10
Activation of autophagy via bacterial lipopolysaccharide in breast cancer cells: A molecular approach to enhancing immunotherapeutic outcomes
Background : Autophagy plays a pivotal role in regulating cancer cell survival and death. Leveraging bacterial components, such as lipopolysaccharide (LPS), to modulate autophagy represents a novel strategy in oncologic therapeutics, especially in breast cancer. Objective : To assess the effect of LPS derived from Escherichia coli on the proliferation, viability, and immune signaling pathways in human breast cancer cell lines MCF-7 and MDA-MB-231, with a focus on autophagy induction and Toll-like receptor activation. Methods : LPS was isolated using the phenol–water method from E. coli strains ATCC 8739 and DH5α. Breast cancer cells were treated with varying concentrations of LPS over multiple time intervals (24–72 h). Viability was measured by MTT and CCK-8 assays, while mRNA expression levels of TLR-4, NF-κB, and PIK3C3 were quantified using qRT-PCR following RNA extraction and cDNA synthesis. Results : LPS treatment significantly reduced cell viability in both breast cancer cell lines in a time- and dose-dependent manner. Gene expression analysis revealed robust upregulation of TLR-4 and NF-κB, implicating activation of immune-related signaling. Moreover, increased PIK3C3 expression indicated stimulation of autophagic pathways. At the molecular level, there was an increase in the conversion of LC3-I to LC3-II and degradation of the autophagy substrate P62/SQSTM1, as confirmed by Western blot analysis, indicating enhanced autophagy. The findings confirm LPS’s ability to trigger immune–autophagic responses leading to cytotoxic effects in cancer cells. Conclusion : LPS from E. coli effectively induces autophagy and activates the immune pathway in breast cancer cells, highlighting its dual potential as an immunomodulator and cytotoxic agent. These findings support further exploration of LPS as an adjuvant in breast cancer treatment strategies, particularly in synergy with conventional chemotherapeutic agents.
- 12 February 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, 1-10
Open AccessActivation of autophagy via bacterial lipopolysaccharide in breast cancer cells: A molecular approach to enhancing immunotherapeutic outcomes
Background : Autophagy plays a pivotal role in regulating cancer cell survival and death. Leveraging bacterial components, such as lipopolysaccharide (LPS), to modulate autophagy represents a novel strategy in oncologic therapeutics, especially in breast cancer. Objective : To assess the effect of LPS derived from Escherichia coli on the proliferation, viability, and immune signaling pathways in human breast cancer cell lines MCF-7 and MDA-MB-231, with a focus on autophagy induction and Toll-like receptor activation. Methods : LPS was isolated using the phenol–water method from E. coli strains ATCC 8739 and DH5α. Breast cancer cells were treated with varying concentrations of LPS over multiple time intervals (24–72 h). Viability was measured by MTT and CCK-8 assays, while mRNA expression levels of TLR-4, NF-κB, and PIK3C3 were quantified using qRT-PCR following RNA extraction and cDNA synthesis. Results : LPS treatment significantly reduced cell viability in both breast cancer cell lines in a time- and dose-dependent manner. Gene expression analysis revealed robust upregulation of TLR-4 and NF-κB, implicating activation of immune-related signaling. Moreover, increased PIK3C3 expression indicated stimulation of autophagic pathways. At the molecular level, there was an increase in the conversion of LC3-I to LC3-II and degradation of the autophagy substrate P62/SQSTM1, as confirmed by Western blot analysis, indicating enhanced autophagy. The findings confirm LPS’s ability to trigger immune–autophagic responses leading to cytotoxic effects in cancer cells. Conclusion : LPS from E. coli effectively induces autophagy and activates the immune pathway in breast cancer cells, highlighting its dual potential as an immunomodulator and cytotoxic agent. These findings support further exploration of LPS as an adjuvant in breast cancer treatment strategies, particularly in synergy with conventional chemotherapeutic agents.
- Open Access
- 23 October 2025
- Published by Pensoft Publishers in Pharmacia
- Vol. 72, 1-11
Targeting HER2: a decade of progress in breast and gastric cancer therapy
Background : Human epidermal growth factor receptor 2 (HER2) is a key member of the epidermal growth factor receptor family and a crucial driver of tumorigenesis in breast and gastric cancers. HER2 amplification and overexpression are associated with poor prognosis, making HER2 an essential therapeutic target. Over the last two decades, significant advancements in HER2-targeted therapies have transformed the treatment landscape, with numerous monoclonal antibodies, tyrosine kinase inhibitors, and antibody–drug conjugates providing substantial survival benefits. Aim : This review aims to summarize the progress in HER2-targeted therapies for breast and gastric cancer over the past decade, highlighting their mechanisms of action, clinical applications, patient selection, and associated side effects. Materials and methods : A comprehensive literature review was conducted using PubMed, Scopus, and Web of Science databases. Studies published between 2013 and 2023, written in English, and focused on HER2-positive breast or gastric cancers were included. Eligible articles comprised clinical trials, systematic reviews, meta-analyses, and real-world studies that evaluated the mechanism, efficacy, safety, or resistance patterns of HER2-targeted therapies such as trastuzumab, pertuzumab, ado-trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and lapatinib. Exclusion criteria were studies involving HER2-negative cancers, non-human or preclinical research without clinical correlation, case reports, editorials, conference abstracts, and non-English publications without available translations. Results : HER2-targeted therapies have shown remarkable efficacy in both early and advanced stages of HER2-positive breast and gastric cancers. Trastuzumab remains the cornerstone of treatment, while pertuzumab improves outcomes in combination regimens. Antibody–drug conjugates such as T-DM1 and T-DXd offer novel mechanisms to deliver cytotoxic agents directly to cancer cells, improving therapeutic indices and reducing systemic toxicity. Tyrosine kinase inhibitors like lapatinib provide unique advantages in treating brain metastases and overcoming resistance. Conclusion : The last decade has seen tremendous progress in HER2-targeted therapies, revolutionizing the management of HER2-positive breast and gastric cancers. Continued innovation and clinical trials promise to extend these advancements, improving patients’ survival and quality of life. The integration of novel agents, personalized approaches, and enhanced understanding of tumor biology will be instrumental in overcoming current limitations and shaping the future of HER2-targeted cancer therapy.
- 23 October 2025
- Published by Pensoft Publishers in Pharmacia
- Vol. 72, 1-11
Open AccessTargeting HER2: a decade of progress in breast and gastric cancer therapy
Background : Human epidermal growth factor receptor 2 (HER2) is a key member of the epidermal growth factor receptor family and a crucial driver of tumorigenesis in breast and gastric cancers. HER2 amplification and overexpression are associated with poor prognosis, making HER2 an essential therapeutic target. Over the last two decades, significant advancements in HER2-targeted therapies have transformed the treatment landscape, with numerous monoclonal antibodies, tyrosine kinase inhibitors, and antibody–drug conjugates providing substantial survival benefits. Aim : This review aims to summarize the progress in HER2-targeted therapies for breast and gastric cancer over the past decade, highlighting their mechanisms of action, clinical applications, patient selection, and associated side effects. Materials and methods : A comprehensive literature review was conducted using PubMed, Scopus, and Web of Science databases. Studies published between 2013 and 2023, written in English, and focused on HER2-positive breast or gastric cancers were included. Eligible articles comprised clinical trials, systematic reviews, meta-analyses, and real-world studies that evaluated the mechanism, efficacy, safety, or resistance patterns of HER2-targeted therapies such as trastuzumab, pertuzumab, ado-trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and lapatinib. Exclusion criteria were studies involving HER2-negative cancers, non-human or preclinical research without clinical correlation, case reports, editorials, conference abstracts, and non-English publications without available translations. Results : HER2-targeted therapies have shown remarkable efficacy in both early and advanced stages of HER2-positive breast and gastric cancers. Trastuzumab remains the cornerstone of treatment, while pertuzumab improves outcomes in combination regimens. Antibody–drug conjugates such as T-DM1 and T-DXd offer novel mechanisms to deliver cytotoxic agents directly to cancer cells, improving therapeutic indices and reducing systemic toxicity. Tyrosine kinase inhibitors like lapatinib provide unique advantages in treating brain metastases and overcoming resistance. Conclusion : The last decade has seen tremendous progress in HER2-targeted therapies, revolutionizing the management of HER2-positive breast and gastric cancers. Continued innovation and clinical trials promise to extend these advancements, improving patients’ survival and quality of life. The integration of novel agents, personalized approaches, and enhanced understanding of tumor biology will be instrumental in overcoming current limitations and shaping the future of HER2-targeted cancer therapy.
- Open Access
- 1 January 2025
- Published by Salud, Ciencia y Tecnologia in Salud, Ciencia y Tecnología - Serie de Conferencias
- Vol. 4, 1167
Thermodynamic and Kinetic Assessment of Cobalt II Adsorption Using Green Synthesized NiO/γ-Al2O3 Nanoparticles
Introduction: Disposal of heavy metals into the water as a result of industrial development might cause a threat Health and the environment. aim of this study was to assess the uptake of Co2+ from aqueous solutions via NiO/ γ-Al2O3 nano catalysts. Methods: The main variables that affect the percentage of metal removal were assessed. It took about 50 minutes to attain equilibrium for the elimination of Co+2 ions. It was discovered that raising the adsorbate concentration and increasing the surface weight somewhat lowered the removal of cobalt ions. Results: The removal of cobalt ions was shown to depend on temperature,due to ecothermic natural of this prosess increasing temperature associated with decrease the elemination . Conclusions: The adsorption seems to be spontaneous, exothermic, and less random according to calculated values of the thermodynamic functions (∆G, ∆H, and ∆S) of the adsorption. After the data were fitted into a number of kinetic models, including the Elovich model, pseudo-first order, pseudo-second order, and intraparticle diffusion equations, it was discovered that the pseudo-second-order model performed the best at describing the adsorption, with a high correlation factor (R2).
- 1 January 2025
- Published by Salud, Ciencia y Tecnologia in Salud, Ciencia y Tecnología - Serie de Conferencias
- Vol. 4, 1167
Open AccessThermodynamic and Kinetic Assessment of Cobalt II Adsorption Using Green Synthesized NiO/γ-Al2O3 Nanoparticles
Introduction: Disposal of heavy metals into the water as a result of industrial development might cause a threat Health and the environment. aim of this study was to assess the uptake of Co2+ from aqueous solutions via NiO/ γ-Al2O3 nano catalysts. Methods: The main variables that affect the percentage of metal removal were assessed. It took about 50 minutes to attain equilibrium for the elimination of Co+2 ions. It was discovered that raising the adsorbate concentration and increasing the surface weight somewhat lowered the removal of cobalt ions. Results: The removal of cobalt ions was shown to depend on temperature,due to ecothermic natural of this prosess increasing temperature associated with decrease the elemination . Conclusions: The adsorption seems to be spontaneous, exothermic, and less random according to calculated values of the thermodynamic functions (∆G, ∆H, and ∆S) of the adsorption. After the data were fitted into a number of kinetic models, including the Elovich model, pseudo-first order, pseudo-second order, and intraparticle diffusion equations, it was discovered that the pseudo-second-order model performed the best at describing the adsorption, with a high correlation factor (R2).